DYN (Dyne Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by DYN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-17 | Johanna Friedl-Naderer | Chief Commercial Officer | Sell | — | — |
| 2026-08-17 | Douglas Kerr | Chief Medical Officer | Sell | — | — |
| 2026-08-17 | Erick Lucera | Chief Financial Officer | Sell | — | — |
| 2026-08-17 | Jason P Rhodes | Director | Sell | — | — |
| 2026-08-17 | John Cox | CEO & President | Sell | — | — |
| 2026-07-29 | Dirk Kersten | Director | Sell | — | — |
| 2026-07-08 | Jason P Rhodes | Director | Sell | — | — |
| 2026-06-26 | Erick Lucera | Chief Financial Officer | Sell | — | — |
| 2026-06-26 | Jason P Rhodes | Director | Sell | — | — |
| 2026-06-24 | Dirk Kersten | Director | Sell | — | — |
| 2026-06-23 | Barry E Greene | Director | A | — | — |
| 2026-06-22 | Dirk Kersten | Director | Sell | — | — |
| 2026-06-17 | Douglas Kerr | Chief Medical Officer | Sell | — | — |
| 2026-06-17 | Johanna Friedl-Naderer | Chief Commercial Officer | Sell | — | — |
| 2026-06-17 | John Cox | CEO & President | Sell | — | — |
| 2026-06-09 | Carlo Incerti | Director | A | — | — |
| 2026-06-09 | David Charles Lubner | Director | A | — | — |
| 2026-06-09 | Brian S Posner | Director | Buy | — | — |
| 2026-06-09 | Catherine Stehman-Breen | Director | A | — | — |
| 2026-06-09 | Jason P Rhodes | Director | A | — | — |
| 2026-06-09 | Dirk Kersten | Director | A | — | — |
| 2026-06-09 | EDWARD HURWITZ | Director | A | — | — |
| 2026-06-05 | Brian S Posner | Director | Buy | — | — |
| 2026-05-28 | Brian S Posner | Director | Buy | — | — |
| 2026-05-22 | Brian S Posner | Director | Buy | — | — |
| 2026-05-14 | Douglas Kerr | Chief Medical Officer | Sell | — | — |
| 2026-05-14 | Erick Lucera | Chief Financial Officer | Sell | — | — |
| 2026-05-14 | Johanna Friedl-Naderer | Chief Commercial Officer | Sell | — | — |
| 2026-05-14 | John Cox | CEO & President | Sell | — | — |
| 2026-05-06 | Jason P Rhodes | Director | Sell | — | — |
| 2026-04-28 | David Charles Lubner | Director | G | — | — |
| 2026-04-27 | Jason P Rhodes | Director | Sell | — | — |
| 2026-04-23 | Dirk Kersten | Director | Sell | — | — |
| 2026-04-22 | Jason P Rhodes | Director | Sell | — | — |
| 2026-04-21 | Dirk Kersten | Director | Sell | — | — |
| 2026-04-17 | Dirk Kersten | Director | Sell | — | — |
| 2026-04-03 | Erick Lucera | Chief Financial Officer | Sell | — | — |
| 2026-04-01 | Brian S Posner | Director | Buy | — | — |
| 2026-03-13 | Brian S Posner | Director | Buy | — | — |
| 2026-03-13 | Dirk Kersten | Director | Sell | — | — |
| 2026-03-11 | Dirk Kersten | Director | Sell | — | — |
| 2026-03-10 | Brian S Posner | Director | Buy | — | — |
| 2026-03-06 | Douglas Kerr | Chief Medical Officer | Sell | — | — |
| 2026-03-06 | Johanna Friedl-Naderer | Chief Commercial Officer | Sell | — | — |
| 2026-03-06 | John Cox | CEO & President | Sell | — | — |
| 2026-02-17 | Erick Lucera | Chief Financial Officer | A | — | — |
| 2026-02-17 | Douglas Kerr | Chief Medical Officer | A | — | — |
| 2026-02-17 | John Cox | CEO & President | A | — | — |
| 2026-02-17 | Johanna Friedl-Naderer | Chief Commercial Officer | A | — | — |
| 2025-12-23 | Vikram Karnani | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 14,959,605 | — |
| — | 10%+ Owner | 8,260,698 | — |
| — | 10%+ Owner | 7,587,471 | — |
| — | 10%+ Owner | 7,326,117 | — |
| — | 10%+ Owner | 6,131,079 | — |
| — | Director | 3,586,796 | — |
| — | 10%+ Owner | 2,805,045 | — |
| — | 10%+ Owner | 2,306,079 | — |
| — | 10%+ Owner | 1,608,785 | — |
| — | 10%+ Owner | 1,504,392 | — |
| — | Director | 1,045,735 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DYN quote page; the site-wide leaderboard is on the insider transactions hub.